In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Janssen Pharmaceutical Cos.

www.janssen.com

Latest From Janssen Pharmaceutical Cos.

Amgen Builds Out Antibody Interests With $2.5bn Teneobio Buy

Private California venture will bring additional expertise and novel platforms to acquisitive biotech giant as it looks to expand its interests in bispecific and multispecific antibody technologies.

Companies M & A

Frustration Over English Funding Rejection For Zytiga And A Win For Ledaga

Janssen and UK health technology assessment body NICE are being urged to sit down together and agree a suitable price for using Zytiga as a first-line treatment for advanced prostate cancer.

Cancer Reimbursement

US FDA Is No Longer ‘Getting Crap’ From Sponsors In IND Safety Reports, Temple Says

FDA’s Robert Temple says he is gratified by the way companies have implemented the agency’s guidance on IND safety reporting. Merck, AbbVie and Janssen representatives discuss issues with unblinding data and the value of an aggregate analysis at DIA’s annual meeting.

Drug Safety Clinical Trials

EU Heart Condition Warning For COVID-19 Vaccines Comirnaty And Spikevax

All four coronavirus vaccines authorized for marketing in the EU/European Economic Area have had their safety information updated because of various adverse events including myocarditis, pericarditis and capillary leak syndrome.

Europe Drug Safety
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register

;